• Foscarnet prophylaxis improved engraftment and survival in cord blood transplant patients

    Six-month overall survival was 96% in the treated group compared to 72% in the untreated group.

  • Latent HHV-6B infection of astrocytes may increase the risk of depression by activating the HPA axis

    Japanese investigators show that a protein expressed by latent HHV-6B in astrocytes, results in an influx of extra-cellular calcium, triggering the onset of depression.

  • Mothers with iciHHV6 have an increased risk of spontaneous abortion

    27.6% of Japanese mothers with iciHHV6 had a spontaneous abortion compared to 14.8% of controls. iciHHV6 mothers were also 6.4X more likely to have two or more spontaneous abortions.

  • Significantly worse outcomes in critically ill hematology patients associated with HHV-6 infection.

    Two reports associate detectable HHV-6 DNA in body fluids with increased risk of mortality in patients being treated for hematologic malignancies.

Newsletter | About Us | Contact Us | Donate | Repository

HHV-6 Foundation | HHV-6 Disease Information for Patients, Clinicians, and Researchers | Apply for a Grant Navigation
  • Home
  • About
    • Scientific Office
    • Scientific Advisory Board
    • Executive Director & Staff
    • Board of Directors
    • Contact Us
    • Donate
  • Patients
    • What Is HHV-6?
    • HHV-6A/B Testing
    • HHV-6 Treatment
    • Patient FAQ
    • Conditions Associated with HHV-6
    • HHV-6 & Immune Suppression
    • Immune Stimulants
    • Chromosomally Integrated HHV-6 (ciHHV-6)
    • CIHHV-6 Testing
  • Research
    • Latest HHV-6 Research
    • Grants
    • Repository
      • Cart
      • Checkout
    • HHV-6A/B Testing
    • List of Genes & Proteins
    • Lab Protocols
    • Pictorial Atlas of HHV-6
    • HHV-6 Antivirals
    • Researcher FAQ
    • Newsletter
  • Clinicians
    • HHV-6A/B Testing
    • HHV-6 Treatment
      • HHV-6 Antivirals
      • Immune Stimulants
    • Alternative Treatments
      • Antiviral use in transplant patients with HHV-6 encephalitis
      • More about foscarnet, ganciclovir and cidovofir
    • HHV-6 & Immune Suppression
    • Chromosomally Integrated HHV-6 (ciHHV-6)
    • CIHHV-6 Testing
    • 10 Surprising Facts about CIHHV-6
  • Conditions
    • Associated Conditions A-H
      • Amnesia
      • Cancer
      • Chromosomally Integrated HHV-6 (ciHHV-6)
      • Chronic Fatigue Syndrome
      • Cognitive Dysfunction
      • Colitis/Diarrhea
      • Drug Hypersensitivity
      • Encephalitis
      • Endocrine Disorders
      • Endothelial Cell Dysfunction
      • Epilepsy
      • Heart Disease
      • HIV/AIDS Progression
    • Associated Conditions I-Z
      • Immune Suppression
      • Kidney Disease
      • Liver Disease
      • Lung Disease
      • Mononucleosis/Lymphadenopathy
      • Multiple Sclerosis
      • Neurological Conditions
      • Organ-Specific Diseases
      • Rash/Roseola
      • Transplant Complications
  • Home
  • About
    • Scientific Office
    • Scientific Advisory Board
    • Executive Director & Staff
    • Board of Directors
    • Contact Us
    • Donate
  • Patients
    • What Is HHV-6?
    • HHV-6A/B Testing
    • HHV-6 Treatment
    • Patient FAQ
    • Conditions Associated with HHV-6
    • HHV-6 & Immune Suppression
    • Immune Stimulants
    • Chromosomally Integrated HHV-6 (ciHHV-6)
    • CIHHV-6 Testing
  • Research
    • Latest HHV-6 Research
    • Grants
    • Repository
      • Cart
      • Checkout
    • HHV-6A/B Testing
    • List of Genes & Proteins
    • Lab Protocols
    • Pictorial Atlas of HHV-6
    • HHV-6 Antivirals
    • Researcher FAQ
    • Newsletter
  • Clinicians
    • HHV-6A/B Testing
    • HHV-6 Treatment
      • HHV-6 Antivirals
      • Immune Stimulants
    • Alternative Treatments
      • Antiviral use in transplant patients with HHV-6 encephalitis
      • More about foscarnet, ganciclovir and cidovofir
    • HHV-6 & Immune Suppression
    • Chromosomally Integrated HHV-6 (ciHHV-6)
    • CIHHV-6 Testing
    • 10 Surprising Facts about CIHHV-6
  • Conditions
    • Associated Conditions A-H
      • Amnesia
      • Cancer
      • Chromosomally Integrated HHV-6 (ciHHV-6)
      • Chronic Fatigue Syndrome
      • Cognitive Dysfunction
      • Colitis/Diarrhea
      • Drug Hypersensitivity
      • Encephalitis
      • Endocrine Disorders
      • Endothelial Cell Dysfunction
      • Epilepsy
      • Heart Disease
      • HIV/AIDS Progression
    • Associated Conditions I-Z
      • Immune Suppression
      • Kidney Disease
      • Liver Disease
      • Lung Disease
      • Mononucleosis/Lymphadenopathy
      • Multiple Sclerosis
      • Neurological Conditions
      • Organ-Specific Diseases
      • Rash/Roseola
      • Transplant Complications

Latest Transplant Complications Articles

View Post

Adding an adoptive NK cell infusion to naïve T-Cell-depleted grafts may reduce the rate of HHV-6B reactivation and encephalitis

A small pediatric study found that adoptive NK cell infusions eliminated HHV-6B encephalitis, while maintaining a low rate of GVHD. At a ratio of NK/CD4 >2, the HHV-6B reactivation rate dropped dramatically.

View Post

HHV-6 found to be the most frequent cause of viremia in children following HSCT

A prospective study of children transplanted for both malignant and nonmalignant disease found HHV-6 viremia in 53% of cases.

View Post

Evidence for HHV-6-induced thrombotic microangiopathy in transplant patients undergoing HSCT

Among infectious agents, HHV-6 was found to be an independent risk factor for thrombotic microangiopathy (TMA) and only HHV-6 infection was associated with TMA-related mortality.

View Post

Breakthrough reactivation of HHV-6 occurs with liver transplantation in spite of valganciclovir preemptive therapy for CMV

High-grade HHV-6 viremia is independently associated with rejection of liver transplants within 12 months

View Post

Adult patients with lower levels of anti-HHV-6 IgG are significantly more likely to experience HHV-6 reactivation following cord blood transplant

Patients with low levels of HHV-6 antibodies might benefit from treatment from IVIG or novel neutralizing antibodies before cord blood transplantation

View Post

Quantitative PCR of serum found superior to whole blood in differentiating between latent virus and viremia following cord blood transplantation

Use of serum more easily distinguishes viremia from latent virus

View Post

HHV-6 reactivation following haploidentical hematopoietic stem-cell transplant found to predict acute graft versus host disease in China

25% of the patients with HHV-6 reactivation developed aGVHD compared to 18% in those without reactivation.

View Post

Substantial reduction in hippocampal volume found in pediatric hematopoietic stem cell transplant patients with HHV-6B reactivation

Surprisingly, the damage from HHV-6B infection often occurred in the absence of obvious neurological symptoms. Patients without HHV-6 reactivation had no reduction in volume.

View Post

Telomeric integration, excision and subsequent and transmission in people with inherited chromosomally integrated HHV-6B (iciHHV-6B)

Exploiting a hypervariable region of the HHV-6B genome, investigators achieve new insights about integration, excision, and genomic stability of iciHHV-6B

View Post

Significantly worse outcomes in critically ill hematology patients associated with HHV-6 infection.

Two reports associate detectable HHV-6 DNA in body fluids with increased risk of mortality in patients being treated for hematologic malignancies.

View Post

HHV-6 is the predominant reactivated virus, other than CMV, in post-transplant cyclophosphamide associated infections

Large, retrospective multi-institutional study of non-CMV herpesvirus infection in the HCT with cyclophosphamide prophylaxis finds higher rate of HHV-6 infection and associated higher mortality

View Post

Failure to detect iciHHV-6 leads to overtreatment in hematopoietic cell transplant recipients

Mistaking iciHHV-6 for a marked reactivation of naturally-acquired infection can lead to unnecessary diagnostic procedures and treatments, with adverse effects.

View Post

Foscarnet prophylaxis improved engraftment and survival in cord blood transplant patients

Six-month overall survival was 96% in the treated group compared to 72% in the untreated group.

View Post

In DRESS/DIHS, early treatment with high dose steroids may suppress HHV-6; late treatment may prolong viremia

High dose steroids given in the first week appears to prevent HHV-6 reactivation in DRESS/DIHS patients by suppressing T-cell activation and serum interleukin-2 receptor (sIL-2R) levels. In contrast, a late start of steroid therapy resulted in a persistently high viral load for at least three weeks.

View Post

CMV & HHV-6 cause severe complications in non-transplant acute leukemia patients

Herpesvirus co-infections, particularly HHV-6 and CMV, cause severe lymphopenia, pneumonia, and an increased risk of acquiring bacterial and fungal infections in non-transplant acute leukemia patients undergoing chemotherapy. 

  • Page 1 of 6
  • 1
  • 2
  • 3
  • ...
  • 6
  • →

Clinical News

  • Alzheimer’s Disease
  • Animal Models
  • Autoimmune Disease
  • Cancer
  • Chronic Fatigue Syndrome
  • iciHHV-6
  • CNS Disease
  • Drug Hypersensitivity
  • Encephalitis & Encephalopathy
  • Endocrine Conditions
  • Epilepsy and Seizures
  • Gastrointestinal
  • Genes
  • Heart Disease
  • Hematological Disorders
  • HIV/AIDS Progression
  • Immunity & Immunotherapy
  • Infertility & Miscarriage
  • Kidney Disease
  • Liver Disease
  • Lung Disease
  • Lymphadenopathy & Fever
  • ME/CFS
  • Multiple Sclerosis
  • Rash & Roseola
  • Transplant Complications
  • Treatments – Adoptive T cell
  • Treatments – Alternative
  • Treatments – Antiviral
  • Treatments – Immune Stimulant

Scientific News

  • Latest Scientific News

About HHV-6

  • What Is HHV-6?
  • What is Inherited Chromosomally Integrated HHV-6
  • HHV-6 Repository of Reagents
  • HHV-6A/B Testing
  • HHV-6 Treatment

SUBSCRIBE TO OUR NEWSLETTER

ABOUT THE HHV-6 FOUNDATION

The HHV-6 Foundation in a non-profit entity founded to encourage scientific exchange between investigators and to provide pilot grants for promising scientific and clinical research on the under- appreciated viruses HHV-6A and HHV-6B.

The Foundation sponsors international conferences and supports scientists and clinicians seeking to clarify the role of the two HHV-6 viruses in disease. Since HHV-6A and HHV-6B can smolder in the brain and other organs without circulating in the peripheral blood or plasma, identifying chronic infection is a challenge.

Read More

HHV-6 Foundation | 1482 East Valley Road, Suite 619 | Santa Barbara, CA, 93108 | Toll Free: (888) 530-6726


Copyright ©2004-2022 HHV-6 FOUNDATION


WEB DESIGN AND DEVELOPMENT BY INSTYLE TECHNOLOGIES
  • Home
  • About
  • Conditions
  • Clinicians
  • Testing
  • Research
  • Repository
  • Patients
  • Treatment
  • News & Blog
  • Donate
  • Contact Us
  • Cart
  • Checkout
  • Privacy Policy
  • Terms of Use